Cycloheximide (CHX) chase analysis revealed that 2-BP treatment resulted in accelerated B7-H4 reduction compared to CHX alone in both human and mouse breast cancer cells (Fig. 2i, j and Supplementary Fig. 2l). Here, VTCN1 is linked to breast cancer.